Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD - University of Lorraine, Nancy, France

Video navigation menu

Mechanistic study of 14 days 01:39
Mechanistic study of 6 weeks 04:12
Analyses of Emperor-Reduced and DAPA-HF 06:06
Conclusions 09:47

Educational information

This presentation was broadcasted at the e-SPACE CRM conference, a global web-conference on the cardio-renal-metabolic syndrome, that was held January 22-24, 2021.

Update

The post hoc analysis of DAPA-HF on the effect of SGLT2i on risk of hyperkalemia associated with MRA use in HFrEF has now been published.

Faculty

Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Concomitant use of diuretics and SGLT2i in HF

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.